| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 1877- | DCA, | Non-Hodgkin′s Lymphoma Reversal with Dichloroacetate |
| - | Case Report, | lymphoma, | NA |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 1879- | DCA, | Long-term stabilization of metastatic melanoma with sodium dichloroacetate |
| - | Case Report, | Melanoma, | NA |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1868- | DCA, | MET, | Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy |
| - | Case Report, | NA, | NA |
| 2152- | dietFMD, | Prolonged Nightly Fasting and Breast Cancer Prognosis |
| - | Analysis, | BC, | NA |
| 1863- | dietFMD, | Chemo, | Effect of fasting on cancer: A narrative review of scientific evidence |
| - | Review, | Var, | NA |
| 1853- | dietFMD, | Impact of Fasting on Patients With Cancer: An Integrative Review |
| - | Review, | Var, | NA |
| 1841- | dietFMD, | Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer |
| - | Trial, | Var, | NA |
| 1810- | dietKeto, | Oxy, | The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer |
| - | in-vivo, | Var, | NA |
| 2165- | dietP, | SFN, | Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study |
| - | Trial, | PC, | NA |
| 5065- | dietSTF, | dietFMD, | Nutrition, GH/IGF-I Signaling, and Cancer |
| - | Review, | Var, | NA |
| 5069- | dietSTF, | The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases |
| - | Review, | Var, | NA |
| 6265- | DL, | Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee |
| - | Trial, | Var, | NA |
| 6270- | DL, | d-limonene exhibits antitumor activity by inducing autophagy and apoptosis in lung cancer |
| - | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | H1299 |
| 5386- | docx, | AsP, | Co-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumor efficacy |
| - | vitro+vivo, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | PC3 |
| 6346- | DRE, | Unusual Response of Acute Monocytic Leukemia to Dandelion Root Extract |
| - | Case Report, | AML, | NA |
| 6348- | DRE, | New prospects in oncotherapy: bioactive compounds from Taraxacum officinale |
| - | Review, | Var, | NA |
| 6318- | DRE, | Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways |
| - | vitro+vivo, | CRC, | HCT116 | - | NA, | Nor, | NCM460 |
| 6322- | DRE, | LGE, | Dandelion Root and Lemongrass Extracts Induce Apoptosis, Enhance Chemotherapeutic Efficacy, and Reduce Tumour Xenograft Growth In Vivo in Prostate Cancer |
| - | vitro+vivo, | Pca, | DU145 |
| 6366- | DRE, | A comprehensive review of the benefits of Taraxacum officinale on human health |
| - | Review, | Var, | NA |
| 6354- | DRE, | Taraxacum officinale L. in leukemia and lymphoma: current knowledge and prospects for horticulture |
| - | Review, | AML, | NA |
| 6357- | DRE, | New Perspectives on the Effect of Dandelion, Its Food Products and Other Preparations on the Cardiovascular System and Its Diseases |
| - | Review, | Nor, | NA |
| 6359- | DRE, | Natural Health Products (NHP’s) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends |
| - | Review, | Var, | NA |
| 4914- | DSF, | immuno, | Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies |
| - | Review, | Var, | NA |
| 4916- | DSF, | Cu, | The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics |
| - | Review, | Var, | NA |
| - | vitro+vivo, | Melanoma, | NA | - | Case Report, | Melanoma, | NA |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1617- | EA, | CUR, | The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin |
| - | in-vitro, | Nor, | NA |
| 1606- | EA, | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
| - | in-vitro, | Colon, | HCT15 |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 3245- | EGCG, | (−)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway |
| - | in-vitro, | Nor, | PC12 |
| 3201- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 6049- | EGCG, | SeNPs, | Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity |
| - | Study, | AD, | PC12 |
| 4290- | EGCG, | EGCG impedes human Tau aggregation and interacts with Tau |
| - | in-vitro, | AD, | NA |
| 1975- | EGCG, | Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate |
| - | in-vitro, | Cerv, | HeLa |
| 1514- | EGCG, | Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 |
| 1516- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 2501- | EGCG, | A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea |
| - | Case Report, | AML, | NA |
| 5227- | EMD, | Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy |
| - | vitro+vivo, | Nor, | NA |
| 6110- | EP, | Leukemic cell intracellular responses to nanosecond electric fields |
| - | in-vitro, | AML, | NA |
| 5525- | EP, | Cell responses without receptors and ligands, using nanosecond pulsed electric fields (nsPEFs) |
| - | Review, | Var, | NA |
| 5527- | EP, | Nanosecond pulsed electric field (nsPEF) application effects on human cells: intracellular membrane disruption and apoptosis induction |
| - | in-vivo, | Var, | NA |
| 5488- | EP, | An in vivo study of a custom-made high-frequency irreversible electroporation generator on different tissues for clinically relevant ablation zones |
| - | in-vivo, | Nor, | NA |
| 5519- | EP, | Nanosecond Pulsed Electric Fields (nsPEFs) for Precision Intracellular Oncotherapy: Recent Advances and Emerging Directions |
| - | Review, | Var, | NA |
| 5522- | EP, | Nanosecond pulsed electric field suppresses growth and reduces multi-drug resistance effect in pancreatic cancer |
| - | in-vitro, | PC, | NA |
| 5523- | EP, | Nanosecond pulsed electric field applications rejuvenate aging endothelial cells by rescuing mitochondrial-to-nuclear retrograde communication |
| - | vitro+vivo, | Nor, | HUVECs |
| 6388- | Eug, | Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review |
| - | Review, | Var, | NA |
| 6379- | Eug, | Safety assessment of a standardized polyphenolic extract of clove buds: Subchronic toxicity and mutagenicity studies |
| - | in-vivo, | Nor, | NA |
| 6376- | Eug, | Preparation, characterization, oral bioavailability, and pharmacodynamic study of eugenol-porous silica solidified powder |
| - | NA, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1114 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid